Sporozoite challenge

OTHER3 trials

Sponsors

University of Oxford, GlaxoSmithKline

Conditions

Malaria

Phase 1

A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites

CompletedNCT00890760

University of OxfordMalaria

Start: 2009-03-31End: 2011-02-28Updated: 2012-11-29

Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP

CompletedNCT01142765

University of OxfordMalaria

Start: 2010-06-30End: 2011-03-31Target: 52Updated: 2011-03-28

Phase 2

Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults

CompletedNCT01366534

GlaxoSmithKlineMalaria

Start: 2011-08-10End: 2012-07-03Updated: 2019-06-18

Related Papers

Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection

JCI Insight2024-10-075 citations

A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.

2016-11-089 citations

A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum

Ghent University Academic Bibliography (Ghent University)2016-01-01

Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults

PLoS ONE2015-07-0693 citations

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

2012-08-0369 citations